Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) COO Grant Yonehiro sold 6,850 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $22,194.00. Following the sale, the chief operating officer directly owned 17,269 shares of […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the sale, the chief financial officer owned 38,000 shares in the […]

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) EVP Peter Heerma sold 8,282 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $65.07, for a total value of $538,909.74. Following the transaction, the executive vice president directly owned 117,066 shares in the company, […]

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) insider William Rote sold 112,850 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $63.33, for a total value of $7,146,790.50. Following the completion of the transaction, the insider directly owned 98,197 shares of the […]

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) insider Elizabeth Reed sold 37,500 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $2,337,750.00. Following the completion of the transaction, the insider owned 105,389 shares in the company, […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $501.39, for a total transaction of $4,763,205.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, […]

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) Director Nilda Mesa sold 228 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the transaction, the director owned 5,580 shares in the company, […]

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) Director Peter Ashley Marks bought 47,620 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average price of $0.50 per share, with a total value of $23,810.00. Following the completion of the purchase, […]